Literature DB >> 973942

Antagonism of fludrocortisone by spironolactone and canrenone.

G J Huston, P Turner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 973942      PMCID: PMC1428813          DOI: 10.1111/j.1365-2125.1976.tb00593.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  PHARMACOLOGICAL PROPERTIES OF A MINERALOCORTICOID ANTAGONIST (SC-14266).

Authors:  C M KAGAWA; D J BOUSKA; M L ANDERSON; W F KROL
Journal:  Arch Int Pharmacodyn Ther       Date:  1964-05-01

2.  QUANTITATION OF MINERALOCORTICOID ACTIVITY AND ANTAGONISM IN NORMAL SUBJECTS.

Authors:  C L GANTT; J M DYNIEWICZ
Journal:  Metabolism       Date:  1963-11       Impact factor: 8.694

3.  Human assay of electrolyte-active steroids and their antagonists.

Authors:  E J ROSS
Journal:  Clin Sci       Date:  1962-10       Impact factor: 6.124

4.  Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Authors:  W Sadée; M Dagcioglu; R Schröder
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

5.  A comparison of the use of Aldactone and Aldactone A in the treatment of hepatic ascites.

Authors:  S SHALDON; J A RYDER; M GARSENSTEIN
Journal:  Gut       Date:  1963-03       Impact factor: 23.059

  5 in total
  4 in total

1.  A comparison of some extra-renal effects of spironolactone and canrenone.

Authors:  G J Huston; E A Al-Dujaili
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

2.  Pharmacokinetics of the new aldosterone antagonist, spirorenone, in healthy volunteers after single and repeated daily doses.

Authors:  W Krause; C Sack; W Seifert
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.

Authors:  W Krause; J Karras; W Seifert
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.

Authors:  P C Ho; D W Bourne; E J Triggs; V Heazlewood
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.